Patients with a history of pancreatitis, thyroid cancer, or severe kidney disease require careful provider evaluation before starting any GLP-1
Tu estmago se vaca ms lentamente
: 99
Flora SJ, Mittal M, Mehta A
FDAs 2025 Increase in Warning Letters on Compounded Drug Advertising In recent remarks at the Food and Drug Law Institutes Enforcement, Litigation, and Compliance Conference, the director of the Office of Compliance within FDAs Center for Drug Evaluation and Research's (CDER) noted that 22% of warning letters that CDER issued in fiscal year (FY) 2025 were sent to telehealth platforms and other entities related to claims made regarding compounded drug products, including compounded GLP-1s
The decision to prescribe compounded medications is an individualized clinical determination made by the treating provider based on the patient's medical history, current health status, and telehealth evaluation